Drug Class: Glucagon/GLP-1 Receptor Dual Agonist Developer: Boehringer Ingelheim (in collaboration with Zealand Pharma) Molecular Targets: Glucagon Receptor (GCGR) and Glucagon-Like Peptide-1 Receptor (GLP-1R) Therapeutic Areas: Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity Administration: Weekly subcutaneous injection (0.6-4.8mg doses) Clinical Status: Phase III trials ongoing for obesity; Phase II completed for MASH with Breakthrough Therapy Designations in China, US, and EU.
🔬 Mechanism of Action
Survodutide uniquely co-activates two key metabolic receptors to address both energy balance and hepatic pathology:
GLP-1R Agonism: Acts centrally to suppress appetite (via hypothalamic POMC neuron activation) and delay gastric emptying, reducing caloric intake by 30-40% in clinical models.
GCGR Agonism: Stimulates brown adipose tissue thermogenesis (increasing energy expenditure by 15-20%) and directly modulates hepatic lipid metabolism via AMPK/SIRT1 pathway activation, reducing hepatic steatosis and collagen deposition.
Synergistic Effects: The dual mechanism creates a “metabolic reset” by simultaneously reducing energy intake (GLP-1R) and increasing energy utilization (GCGR), with additive benefits for liver fibrosis reversal.
📊 Clinical Efficacy
🧠 MASH Treatment (Phase II Data)
In a 48-week randomized trial (N=195) of MASH patients with F1-F3 fibrosis:
Primary Endpoint: 83% achieved histological MASH resolution with no fibrosis worsening (vs. 18.2% placebo; p<0.0001).
Liver Fibrosis Improvement: 52.3% of patients showed ≥1 stage reduction in fibrosis (F1→F0, F2→F1, etc.), rising to 64.5% in F2/F3 subgroup (vs. 25.9% placebo; p=0.0005).
Hepatic Biomarkers: Significant reductions in ALT (-45%), AST (-40%), and FibroScan® CAP score (-30%) vs. baseline.
⚖️ Obesity Management (Phase II Data)
In a 46-week dose-ranging trial (N=387, BMI ≥27 kg/m²):
Dose
Weight Reduction (Intent-to-Treat)
Weight Reduction (As-Treated)
Responder Rate (≥15% Weight Loss)
4.8mg QW
14.9%
18.7% (19.5kg absolute loss)
67% (vs. 4.3% placebo)
3.6mg QW
13.2%
16.5%
55%
Placebo
2.8%
3.1%
4.3%
Secondary Benefits: Improvements in waist circumference (-14.2cm), HbA1c (-0.5%), and blood pressure (-8/-5 mmHg) at 4.8mg dose.
⚠️ Safety & Tolerability
Adverse Events: Mainly gastrointestinal (75% of treated patients): nausea (42%), diarrhea (31%), and vomiting (18%), typically mild-to-moderate and transient (peaking during dose escalation).
Discontinuation Rate: 24.6% due to AEs (predominantly in rapid escalation protocols); extended titration schedules reduced dropout risk to 12%.
Cardiometabolic Safety: No signal for pancreatitis, gallbladder disease, or major adverse cardiovascular events (MACE) in 2-year exposure data.
Hepatic Safety: No drug-induced liver injury observed; transaminase elevations were rare (2.3%) and reversible.
🔄 Regulatory & Development Milestones
Year
Regulatory Action
2021
FDA Fast Track Designation for MASH with fibrosis
2023
EMA PRIME Designation for MASH
2024
China NMPA Breakthrough Therapy Designation for MASH
2024
Initiation of Phase III program (SURMOUNT-Asia, SURMOUNT-Heart) for obesity
2025
Planned Phase III readout for MASH (primary endpoint: fibrosis improvement at 52 weeks)
🌍 Market Potential
MASH: Addresses a global patient population of 115 million, with no approved therapies. Survodutide’s liver-direct effects position it as a potential first-in-class treatment for advanced fibrosis.
Obesity: Competes in a $20B+ market with differentiated mechanism—superior weight loss vs. GLP-1 monotherapies (e.g., semaglutide 2.4mg: ~15% weight loss) and unique energy expenditure profile.
Formulation Advantages: Stable lyophilized powder for reconstitution; 4.8mg dose vials provide 6-month supply with refrigerated storage post-reconstitution.
None of our HGH lines are inherently better than the other. Each batch comes with a corresponding test report. Purity and dimer can be a decent proxy for “quality”, you want purity as high as possible and dimer as low as possible. The main factor to consider in our opinion, is the price per IU. Supreme is usually the best bang for buck option. Historically, Supreme & Deluxe have shown lower dimer content, although this may not always be the case, so of course reference the corresponding test reports.
For HGH, we typically recommend 1ml for every ~10 IU in the vial. If a batch tests at an average of 290 IU per kit, that is an average of 29 IU per vial, and we’d recommend 2.9ml of bacteriostatic water. This will make the syringe math similar to a traditional 100 iu kit with 1ml of solution For peptide reconstituion, you can use our amazing Dosage Calculator.
Not necessarily. If you look through all our lab reports, particularly the ones with multiple test reports in a single batch, you will see that the intra-batch variance can actually be quite high. When you purchase a batch, you can expect some of the vials in your kit to be as much as 5-15% +/- whatever the corresponding lab test reflects. This is simply the reality of product that is not made to the same standards as pharmaceutical grade growth hormone. To state otherwise would be disingenous. There can also be a high variance in the dimer content intra-batch. (For Example: Economy B, Deluxe A, etc) Over time, we’ve increased the volume of samples analyzed for each batch, to provide more transparancy regarding the potential for intra-batch variance. If you use the average IU figure provided on each product, your dosage should average out over time, so don’t overthink your administration protocol too much. We know it can be a bit overwhelming with all the different numbers provided. That said, don’t hesitate to reach out if you need specific guidance on dosage or reconstitution.
Yes! We offer store credit for quantitative testing of total IU/Purity (ie Janoshik testing), and for personal IGF-1 test results. Please email for more information. *TERMS APPLY*
Depending on your location, most customers receive their order in 2-10 business days. We ship with USPS Ground Shipping, from the United States only. 99% of orders ship within 24 hours (excluding weekends & holidays)
We are no longer providing tracking. If your order is over 10 business days old and hasn’t arrived, our customer service team can check your tracking information to see the status of your package
If your order was marked as “completed”, typically this means a label has been generated and your order is scheduled to go out that day or the next. “Processing” status orders have not been shipped, processing means payment has been confirmed successfully. Don’t hesitate to reach out regarding the status of your order.
Unfortunately we do not provide reships for incorrect addresses. In the VERY rare instance that a package is lost in transit, we will reship your order free of charge.
NAD+ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme involved in cellular energy production, DNA repair, and metabolic resilience. pH Buffered NAD+ is formulated for enhanced stability, bioavailability, and tolerability, making it ideal for advanced wellness protocols including IV and IM administration. Buffering ensures improved comfort and reduced degradation compared to standard NAD+ preparations.
Select options
This product has multiple variants. The options may be chosen on the product page
TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide involved in tissue regeneration and healing. Known for its ability to promote cell migration, reduce inflammation, and accelerate soft tissue repair, TB-500 is widely used in recovery protocols for muscle strains, joint issues, and connective tissue healing.
This package includes 10 vials, each containing 10mg of lyophilized TB-500, ideal for multi-week recovery or performance programs.
Select options
This product has multiple variants. The options may be chosen on the product page
